SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying as investors react to a strategic $14.2 billion deal to regain full ownership of its Ireland-based Fab 34, a move perceived as a major vote of confidence in the company's manufacturing and AI-driven growth trajectory. The community is actively debating the stock's future, with many interpreting the heavy capital reinvestment as a clear indicator that major new customer contracts are imminent.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is currently trending following news that it has secured FDA approval for VYKAT XR, the first therapy developed to treat hyperphagia in Prader-Willi syndrome. The community is actively discussing the stock's significant price momentum, debating the potential for a future acquisition by a larger pharmaceutical player, and evaluating the long-term commercial execution of this newly approved asset.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as the market reacts to the company's latest subscription price hikes, which analysts view as a strategic move to fund a massive content budget and solidify profitability. While some retail investors are voicing frustration over recurring cost increases, the community is heavily focused on the stock's relative strength and technical breakout potential, with many discussing its role as a hedge against broader market volatility.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind this Solana-based meme coin as a satirical movement intended to mock established market structures, with community members actively comparing its long-term potential to industry giants. Discussions are currently dominated by enthusiasts promoting the token's cultural narrative and its goal of creating viral engagement within the broader crypto ecosystem.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending as the market reacts to the definitive agreement to acquire Soleno Therapeutics for $2.9 billion. Community sentiment is mixed, with active debate regarding whether the acquisition effectively addresses Neurocrine's need for pipeline growth or if the premium paid for the rare-disease asset signals a strategic overpay.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altria Group is seeing significant investor interest driven by a combination of resilient pricing power in its core smokeable business and ongoing momentum in its smoke-free portfolio, particularly with the growth of its on! nicotine pouches. The community is actively debating the company's long-term pivot from traditional cigarettes toward smoke-free alternatives, with many highlighting the stock's role as a classic, high-yield defensive play in a volatile market.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is experiencing a significant surge in momentum as the company reports positive trial results for its essential tremor and epilepsy therapies, driving multiple analyst price target upgrades. While the community is debating the impact of a recent large-scale public offering, many investors remain bullish on the long-term potential of the company's CNS-focused pipeline.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is currently trending as shareholders analyze the strategic implications of parent company Centurium Capitals acquisition of Blue Bottle Coffee. While the community remains divided over potential conflicts of interest versus synergistic growth, investors are closely monitoring for signs of a long-anticipated U.S. exchange relisting and are actively debating the stock's future valuation amid shifting institutional ownership.

A2Z Cust2Mate Solutions Corp. is a technology company, which engages in the development and commercialization of retail smart cart solutions for large grocery stores and supermarkets. It operates through the Smart Carts and Precision Metal Parts segments. The Smart Carts segment offers retail automation solutions. Its platform enables seamless in-cart scanning and payment, allowing shoppers to bypass checkout lines while receiving real-time customized offers and product recommendations. The Precision Metal Parts segment includes the manufacturing and sale of precision metal parts. The company was founded by Joseph Bentsur on January 15, 2018 and is headquartered in Vancouver, Canada.

A2Z Cust2Mate Solutions Corp.

A2Z Smart Technologies Corp.

A2Z Smart Technologies is trending following a major five-year strategic agreement to deploy 4,000 smart shopping carts at Carrefour Israel, a move the community views as a significant model for global scalability. Investors are actively discussing the company's retail media expansion, potential for recurring revenue, and bullish technical setups, with many highlighting institutional interest from significant fund stakes as a vote of confidence in the stock's long-term growth trajectory.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is currently trending due to intense speculation surrounding a potential short squeeze, driven by extremely limited share availability for borrowing and surging borrow fees. The community is actively debating the stock's volatility, with many retail traders drawing comparisons to historical meme stock runs while critics emphasize the company's lack of revenue and potential for dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is iShares Core S&P U.S. Value ETF (IUSV) a Strong ETF Right Now?

Is Schwab Fundamental U.S. Broad Market ETF (FNDB) a Strong ETF Right Now?

DocuSign, Inc. (DOCU) stock plummeted in Friday's premarket session despite the cloud platform provider’s better-than-expected quarterly results, but retail traders rallied behind the company.The company also&nbsp;raised its full-year revenue forecast. Some of the stock weakness may have to do with the subpar quarterly billings.&nbsp;DocuSign’s board authorized a new buyback program to buy up to $1 billion.The San Francisco, California-based company’s platform allows individuals and businesses to sign and share documents electronically.Retail sentiment toward DocuSign stock stayed ‘extremely bullish’ (99/100) by early Friday, with the message volume also staying at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:618/55;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_06_at_5_15_54_AM_png_bd6a3af97f.webp" alt="Screenshot 2025-06-06 at 5.15.54 AM.png" width="618" height="55"><figcaption>DOCU sentiment and message volume as of 5:15 a.m. ET, June 6 | source: Stocktwits</figcaption></figure>A bullish user said, “How can you not like this buying opportunity?? What a gift!,” referring to the after-hours slump.<stembedurl>https://stocktwits.com/DiamondHandsDO/message/617015409</stembedurl>Another user said they bought the dip, keeping fingers crossed.<stembedurl>https://stocktwits.com/MeowNow/message/617017130</stembedurl>DocuSign reported adjusted earnings per share (EPS) of $0.90 for the first quarter of fiscal year 2026, up from $0.82 earned a year ago and ahead of the Finchat-compiled consensus of $0.91.Revenue climbed 8% year over year (YoY) to $763.7 million versus the $748.92-million average analysts’ estimate and the $745 million-$749 million guidance.Billings climbed 4% to $739.6 million, trailing the company’s forecast of $741 million to $751&nbsp;million.CEO Allan Thygesen said, “Q1 was an important quarter for Docusign's long-term transformation as we delivered on an ambitious product roadmap and surpassed 10,000 Intelligent Agreement Management customers.”The company’s second-quarter revenue guidance was in line with the consensus, and it marginally upped its 2026 revenue guidance to $3.151 billion-$3.163 billion from $3.129 billion-$3.141 billion. The new full-year revenue guidance exceeded the $3.137 billion consensus.DocuSign stock plunged over 18% to $75.93 in Friday's early premarket session, while it is up over 3% year-to-date. If the premarket losses are sustained in Friday’s session, the stock could be on track for its worst day in more than two years.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/retail-dip-buyers-flock-to-broadcom-after-stocks-drops-despite-2025-q2-beat/chkz1vaRbxF"> Retail Dip Buyers Flock To Broadcom After Stock Drops Despite AI-Powered Q2 Beat</a>

Facade of DocuSign building with logo visible, South of Market, San Francisco, California, June 7, 2024.

DocuSign Stock Plummets Despite Beat-and-Raise Quarter But Retail Goes All-Out Into The Stock

CEO Allan Thygesen said Q1 was an important quarter for the company’s transformational initiatives and that DocuSign surpassed 10,000 Intelligent Agreement Management customers.

Equity

CEO Allan Thygesen said Q1 was an important quarter for the company’s transformational initiatives and that DocuSign surpassed 10,000 Intelligent Agreement Management customers.


Is iShares U.S. Equity Factor ETF (LRGF) a Strong ETF Right Now?

Is Fidelity High Dividend ETF (FDVV) a Strong ETF Right Now?

Is Vident U.S. Equity Strategy ETF (VUSE) a Strong ETF Right Now?

DocuSign, Inc. (DOCU) stock&nbsp;may draw significant attention on Monday&nbsp;following an expanded tie-up with IT consulting and outsourcing&nbsp;giant Cognizant Technology Solutions Corp. (CTSH).Teaneck, New Jersey-based Cognizant said Friday it has expanded the existing 360-degree partnership with intelligent agreement management (IAM) company DocuSign.&nbsp;Under the expanded partnership, the companies will work to provide innovative IAM solutions that optimize customer service management and streamline agreement processes globally.Specifically, Cognizant and DocuSign will focus on real-time customer assistance, training to help customers deploy DocuSign solutions, expanded back-office support to enhance service management and onboarding new customers.Kelly Morgan, chief customer officer of Docusign, said, “Together we have the opportunity to expedite the advancement of our Docusign IAM platform and deliver more intelligent and efficient solutions to our customers.”Anurag Sinha, senior vice president and business unit head of communications, media and technology at Cognizant said, "By introducing advanced digital solutions, we are optimizing service delivery and ensuring Docusign's customers receive the support they need."In mid-March, DocuSign reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/docusign-stock-spikes-on-2025-q4-earnings/ch7IP5lRbR6">forecast-beating fourth-quarter results</a> and issued positive guidance.&nbsp;On Stocktwits, sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/DOCU">DocuSign stock</a> remained ‘bullish’ (59/100) but message volume was ‘extremely low.’<figure class="image"><img style="aspect-ratio:640/138;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_21_at_1_31_12_AM_png_d966455191.webp" alt="Screenshot 2025-04-21 at 1.31.12 AM.png" width="640" height="138"><figcaption>DOCU sentiment and message volume as of 1:30 a.m. ET, April 21 | Source: Stocktwits</figcaption></figure>A bullish watcher said they braced for long-term gains for the stock.<stembedurl>https://stocktwits.com/DFWxplorer/message/612088107</stembedurl>Sentiment toward <a href="https://stocktwits.com/symbol/CTSH">Cognizant stock </a>stayed ‘extremely bullish' (91/100), with the message volume at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:643/134;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_21_at_1_28_41_AM_png_3a12dba98a.webp" alt="Screenshot 2025-04-21 at 1.28.41 AM.png" width="643" height="134"><figcaption>CTSH sentiment and message volume as of 1:30 a.m. ET, April 21 | Source: Stocktwits</figcaption></figure>DocuSign stock ended Thursday’s session down 1.72% at $75.42, and it has lost 16% for the year-to-date period. Cognizant is down a more modest 9% this year.The Koyfin-compiled consensus price target of $92.95 for DocuSign stock suggests it trades at a 19% discount&nbsp;to current levels.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/china-warns-of-blowback-to-countries-engaging-in-us-trade-talks/chQi4T7RbQG">China Warns Of Blowback To Countries Engaging In US Trade Talks, Urges Resisting 'Unilateral Bullying'</a>

DocuSign expects the new agreement to expedite the advancement of its IAM platform and deliver more intelligent and efficient solutions to its customers. 

DocuSign Stock In Spotlight On Expanded Cognizant Partnership: Retail Stays Positive

Under the expanded partnership, the companies will work to provide innovative intelligent agreement management solutions that optimize customer service management and streamline agreement processes globally.

DocuSign, Inc. (DOCU) shares climbed sharply in Thursday’s after-hours session after the cloud platform provider that allows individuals and businesses to sign and share documents electronically announced&nbsp;forecast-beating fourth quarter results and issued positive guidance.The San Francisco, California-based company reported adjusted earnings per share (EPS) of $0.86 for the fourth quarter of the fiscal year 2025. This marked an improvement from the year-ago quarter’s $0.76. The EPS also beat the Finchat-compiled consensus of $0.85.Revenue was $776.3 million, a 9% increase year-over-year compared to the 8% growth in the third quarter. The topline exceeded the $761.64 million consensus estimate and the forecast of $758 million to $762 million the company issued in early December.Subscription revenue of $757.8 million grew 8%.Among operational metrics, billings rose 11% to $923.2 million compared to the guidance of $870 million to $880 million.&nbsp;The non-GAAP gross and operating margins were 82.3% and 28.8%, respectively, also beating the guidance.&nbsp;DocuSign generated free cash flow of $279.6 million during the quarter. It ended the quarter with a cash position of $1.1 billion.Allan Thygesen, CEO of Docusign, said, “Fiscal 2025 was a transformative year for Docusign.” The executive noted that the company’s artificial intelligence-powered agreement management platform&nbsp;&nbsp;Docusign IAM&nbsp;launched during the quarter was gaining traction.Looking ahead, DocuSign guided first-quarter and full-year revenue of $745 million to $749 million and $3.129 billion to $3.141 billion, compared to the consensus of $755.74 million and $3.150 billion, respectively.The company expects billings of $741 million to $751 billion for the first quarter and $3.30 billion to $3.07 billion for the full year.On Stocktwits, retail sentiment toward <a href="https://stocktwits.com/symbol/DOCU">DocuSign stock </a>stayed ‘extremely bullish’ (97/100), with optimism improving from a day ago. The message volume also remained ‘extremely high.’ The stock was among the top 10 trending tickers on the platform late Thursday.<figure class="image"><img style="aspect-ratio:632/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/docu_sentiment_png_c9704b2309.webp" alt="docu-sentiment.png" width="632" height="135"><figcaption>DOCU sentiment and message volume March 13, as of 9:51 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>A bullish watcher called the earnings “good,” referring to DocuSign as a “growth stock.”<stembedurl>https://stocktwits.com/DoomBot1/message/608026566</stembedurl>Another user predicted a stock move toward $90.<stembedurl>https://stocktwits.com/Geraldgenofranco1975/message/608025755</stembedurl>DocuSign ended Thursday’s after-hours session up 11.90% at $83.59. If the gains carry over to Friday’s regular session, the stock is on track to record its biggest single-day gains in three months, according to Koyfin.The stock, however, is down about 17% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/d-wave-stock-surges-on-upbeat-guidance-mixed-q4-results/ch7dNosRbRx">D-Wave Stock Surges On Upbeat Guidance, Mixed Q4 Results: Retail Optimism Abounds</a>

Exterior view of DocuSign building with logo visible, Rincon Hill, San Francisco, California, June 7, 2024. 

DocuSign Stock Rips Higher After-Hours On Q4 Beat, Positive Outlook: Retail Lauds ‘Good’ Report

CEO Allan Thygesen said the company’s artificial intelligence-powered agreement management platform launched during the quarter was gaining traction.

iShares Trust - iShares Core S&P U.S.Value ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

IUSV
iShares Core S&P US Value ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IUSV News

IUSViShares Core S&P US Value ETF